Back to Search
Start Over
A decision-theoretic approach to Bayesian clinical trial design and evaluation of robustness to prior-data conflict.
- Source :
-
Biostatistics . Jan2022, Vol. 23 Issue 1, p328-344. 17p. - Publication Year :
- 2022
-
Abstract
- Bayesian clinical trials allow taking advantage of relevant external information through the elicitation of prior distributions, which influence Bayesian posterior parameter estimates and test decisions. However, incorporation of historical information can have harmful consequences on the trial's frequentist (conditional) operating characteristics in case of inconsistency between prior information and the newly collected data. A compromise between meaningful incorporation of historical information and strict control of frequentist error rates is therefore often sought. Our aim is thus to review and investigate the rationale and consequences of different approaches to relaxing strict frequentist control of error rates from a Bayesian decision-theoretic viewpoint. In particular, we define an integrated risk which incorporates losses arising from testing, estimation, and sampling. A weighted combination of the integrated risk addends arising from testing and estimation allows moving smoothly between these two targets. Furthermore, we explore different possible elicitations of the test error costs, leading to test decisions based either on posterior probabilities, or solely on Bayes factors. Sensitivity analyses are performed following the convention which makes a distinction between the prior of the data-generating process, and the analysis prior adopted to fit the data. Simulation in the case of normal and binomial outcomes and an application to a one-arm proof-of-concept trial, exemplify how such analysis can be conducted to explore sensitivity of the integrated risk, the operating characteristics, and the optimal sample size, to prior-data conflict. Robust analysis prior specifications, which gradually discount potentially conflicting prior information, are also included for comparison. Guidance with respect to cost elicitation, particularly in the context of a Phase II proof-of-concept trial, is provided. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14654644
- Volume :
- 23
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Biostatistics
- Publication Type :
- Academic Journal
- Accession number :
- 156110889
- Full Text :
- https://doi.org/10.1093/biostatistics/kxaa027